Investor Relations

Founder-led. Capital-efficient. De-risked pathway to market.

Market Opportunity

Size of the AST Market

$0BGlobal AST market, driven by AMR
$0BUS rapid clinical microbiology market
$0MUS sepsis AST market
Scope of Unmet Need

A Crisis Demanding Innovation

0MAMR attributable deaths per year
0Msepsis cases globally
$0Tannual costs of sepsis care
Cytophenix team member presenting scientific research findings
Leadership & Board

Founder-Led with Deep Expertise

We are founder-led (>85% ownership), blending microbiology and data science expertise with commercial acumen. To date we have secured $10 million non-dilutive, $1.3 million pre-seed ($AUD).

Our flow cytometry partnership reduces R&D, manufacturing, and distribution costs. It drives down regulatory risk and attendant delay to revenues generation seen with other market entrants.

Investment Thesis

Reasons to Invest

De-Risked Pathway

Strategic partnership for manufacturing and distribution.

First US KOL pilot installed Q1 2026.

Proven Technology

4-hour AST results.

35 hours faster than current methods, validated in clinical settings.

Market Fit

Widely-adopted technology platform.

Sample-to-answer, AI-enabled results interpretation.

Economic Value

Per-case savings from $2,704 – $304,722, depending on acuity of care.

Realistic Expectations

Projections are right-sized for the sepsis-related US microbiology diagnostic market for AST.

References

  1. Kumar et al. 2006, "Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock" PMID: 16625125.
  2. Liu et al. 2017, "The Timing of Early Antibiotics and Hospital Mortality in Sepsis". PMID 28345952.

Interested in Learning More?

Contact our investor relations team to discuss opportunities.

Investor Enquiries